SWOG clinical trial number
SWOG-9313

Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A’C) in High-Risk Breast Cancer Patients with 0 - 3 Positive Nodes (Intergroup)

Closed
Phase
Accrual
98%
Published
Abbreviated Title
Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A’C) in High-Risk Breast Cancer…
Activated
03/15/1994
Closed
05/01/1997

Research committees

Breast Cancer

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;H Pathak;K Isakova;K Timms;A Hartman;R Wenstrup;H Linden;D Tripathy;G Hortobagyi;DF Hayes Annals of Oncology Mar 1;29(3):654-660; Dec 23 [Epub ahead of print] 2017

PMid: PMID29293876

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2017

Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;H Pathak;K Isakova;AR Hartman;R Wenstrup;H Linden;D Tripathy;G Hortobagyi;D Hayes Proceedings of the American AACR Association for Cancer Research April 2017 Vol 58, abst. 1776 p. 456; AACR Annual Meeting (April 1-5, 2017, Washington, DC), poster

Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;L Knight;SM Walker;RD Kennedy;S Badve;Y Gokmen-Polar;H Pathad;S Isakova;H Linden;D Tripathy;G Hortobagyi;D Hayes J Clin Oncol 35, 2017 (suppl; abstr 529); American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session

2014

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

2013

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

2010

Multiplexed assessment of the Southwest Oncology Group directed intergroup breast cancer trial S9313 by AQUA show both high and low levels of HER2 are associated with poor outcome [PMC2843456; PMID20150438]

M Harigopal;W Barlow;G Tedeschi;P Porter;I Yeh;C Haskell;R Livingston;G Hortobagyi;G Sledge;C Shapiro;J Ingle;D Rimm;DF Hayes American Journal of Pathology 176(4):1639-1647;

2009

Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status [PMC2734394; PMID19620488]

RR Tubbs;W Barlow;GT Budd;E Swain;P Porter;AM Gown;IT Yeh;G Sledge;S Shapiro;J Ingle;C Haskell;KS Albain;RB Livingston;DF Hayes Journal of Clinical Oncology, 27(24):3881-3886

2008

Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous variable assessment

DL Rimm;M Harigopal;G Tedeschi;PL Porter;I-T Yeh;CM Haskell;W Barlow;RB Livingston;GN Hortobagyi;DF Hayes San Antonio Breast Cancer Symposium, abstract #75

2007

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313) [PMID17308269]

HM Linden;CM Haskell;S Green;CK Osborne;GW Sledge;CL Shapiro;JN Ingle;D Lew;LF Hutchins;RB Livingston;S Martino Journal of Clinical Oncology 25(6):656-661

TOP2A gene amplification and response to adriamycin based therapy

RR Tubbs;W Barlow;GT Budd;E Swain;P Porter;I Yeh;G Sledge;C Shapiro;J Ingle;C Haskell;KS Albain;RB Livingston;DF Hayes San Antonio Breast Cancer Symposium #2005

2006

p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy

PL Porter;WE Barlow;IT Yeh;MG Lin;XP Yuan;E Donato;GW Sledge;CL Shapiro;JN Ingle;CM Haskell;KS Albain;JM Roberts;RB Livingston;DF Hayes Journal of the National Cancer Institute 98(23):1723-1731

2005

Prognostic value of cell cycle regulators p27 and cyclin E: tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313

PL Porter;W Barlow;IT Yeh;MG Lin;X Yuan;JN Ingle;CL Shapiro;GP Sledge;RB Livingston;DF Hayes Proc of the ASCO, JCO 23(16S):5s (#507)

2002

Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by chyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137)

CM Haskell;SJ Green;GW Sledge Jr;CL Shapiro;JN Ingle;D Lew;S Martino;R Livingston;CK Osborne Proc of the American Society of Clinical Oncology 21:36a(#142)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7436

Combined Modality Therapy of Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
01/09/1975
Closed
07/18/1979
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
07/16/1979
Closed
08/01/1989
Accrual
100%
Closed
Phase
III
Published